| Jonathan Subaitani, PA-C | |
|
6051 W Emerald St, Boise, ID 83704-8969 | |
| (208) 302-5150 | |
| (208) 302-5155 |
| Full Name | Jonathan Subaitani |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 8 Years |
| Location | 6051 W Emerald St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821529918 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern Idaho Health Partners Llc | 5395063564 | 83 |
News Archive
When asked to inhibit their response to a "cocaine-cues" video, active cocaine abusers were, on average, able to suppress activity in brain regions linked to drug craving, according to a new study at the U.S. Department of Energy's Brookhaven National Laboratory. The results, to be published in an upcoming issue of NeuroImage, suggest that clinical interventions designed to strengthen these inhibitory responses could help cocaine abusers stop using drugs and avoid relapse.
How many times patients with gastrointestinal disorders have been told "There is nothing wrong, nothing organic, it's all you head". But the pain is real.
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Subaitani, PA-C Po Box 190930, Boise, ID 83719-0930 Ph: (208) 367-5170 | Jonathan Subaitani, PA-C 6051 W Emerald St, Boise, ID 83704-8969 Ph: (208) 302-5150 |
News Archive
When asked to inhibit their response to a "cocaine-cues" video, active cocaine abusers were, on average, able to suppress activity in brain regions linked to drug craving, according to a new study at the U.S. Department of Energy's Brookhaven National Laboratory. The results, to be published in an upcoming issue of NeuroImage, suggest that clinical interventions designed to strengthen these inhibitory responses could help cocaine abusers stop using drugs and avoid relapse.
How many times patients with gastrointestinal disorders have been told "There is nothing wrong, nothing organic, it's all you head". But the pain is real.
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified for stem cell transplants.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
› Verified 4 days ago